NCT05610072 (BED IN 43) is a EARLY_PHASE1 clinical trial of n-acetylcysteine in Cocaine Use Disorder, sponsored by William Stoops.

Who is sponsoring NCT05610072?

NCT05610072 is sponsored by William Stoops.

What drugs are being tested in NCT05610072?

Interventions in NCT05610072: n-acetylcysteine, Hydromorphone, Placebo n-acetylcystine, Placebo hydromorphone.

What condition does NCT05610072 study?

NCT05610072 studies Cocaine Use Disorder, Opioid Use Disorder, Stimulant Use Disorder.

Is NCT05610072 still recruiting?

NCT05610072 is currently recruiting now. Last updated 11 December 2025.

Last reviewed 2025-12-11 · How we verify

NCT05610072: BED IN 43

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Recruiting now EARLY_PHASE1 Last updated 11 December 2025

What this trial tests

EARLY_PHASE1 trial testing n-acetylcysteine in Cocaine Use Disorder in 24 participants. Currently enrolling.

Timeline

15 December 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	William Stoops
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	24
Start date	15 December 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	2 locations across United States

Drugs / interventions tested

n-acetylcysteine — full drug profile →
Hydromorphone (HYDROMORPHONE) — full drug profile →
Placebo n-acetylcystine
Placebo hydromorphone

Conditions studied

Cocaine Use Disorder — all drugs for Cocaine Use Disorder →
Opioid Use Disorder — all drugs for Opioid Use Disorder →
Stimulant Use Disorder — all drugs for Stimulant Use Disorder →

Sponsor

William Stoops

Who can join

Adults 18 to 55, any sex, with Cocaine Use Disorder or Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce both opioid and cocaine demand. These hypotheses will be tested with two specific aims. Specific Aim 1. Determine the reinforcing effects of cocaine in individuals with comorbid opioid and cocaine use disorder with physiological dependence on opioids during NAC maintenance. All subjects will be maintained on oral hydromorphone. They will also be randomly assigned to receive placebo or oral NAC (2.4 g/day), stratified by sex. After dose stabilization, experimental sessions will be conducted in which subjects complete hypothetical cocaine purchase tasks during opioid maintenance and opioid withdrawal. The hypotheses are: 1) cocaine purchasing will be greater during opioid withdrawal and 2) NAC maintenance will attenuate cocaine purchasing across opioid maintenance and withdrawal periods. Specific Aim 2. Evaluate glutamate functionality during periods of opioid maintenance and withdrawal in individuals with comorbid opioid and cocaine use disorder and physiological dependence on opioids during NAC maintenance. Subjects will undergo magnetic resonance spectroscopy to evaluate brain glutamate changes as a function of opioid maintenance/withdrawal state and NAC maintenance. The hypotheses are: 1) glutamate levels will be elevated during opioid withdrawal and 2) NAC maintenance will ameliorate elevated glutamate levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of n-acetylcysteine

Trials testing the same drug.

NCT05903014 — Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction · Phase 4 · completed

Other recruiting trials for Cocaine Use Disorder

Currently open trials in the same condition.

NCT07227948 — Repurposing Semaglutide for the Treatment of Cocaine Use Disorder · Phase 2 · recruiting
NCT07086794 — Cocaine and Pentoxifylline (BED IN 47) · EARLY_PHASE1 · recruiting
NCT06050304 — CRACK-TARGET 1: Descriptive Study of Observed Behavioral Sensitization and Expectations · NA · recruiting
NCT07091877 — Cocaine Cue-reactivity Incubation Study · NA · recruiting
NCT05986578 — Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder · NA · recruiting

Other William Stoops trials

Trials by the same sponsor.

NCT07226596 — Non-Abstinence Outcomes in Methamphetamine Use Disorder · NA · recruiting
NCT07086794 — Cocaine and Pentoxifylline (BED IN 47) · EARLY_PHASE1 · recruiting
NCT06989853 — Methamphetamine and Troriluzole · EARLY_PHASE1 · recruiting
NCT06326684 — Suvorexant and Alcohol · EARLY_PHASE1 · recruiting
NCT05019430 — Cocaine and Zolmitriptan · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05610072 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by William Stoops
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05610072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing